AAX Biotech AB

AAX Biotech AB is a biotech company spun out from Karolinska Institutet by co-founders Mats AA Persson and Daniel X Johansson. The company specializes in next-generation antibody therapeutics through its two unique and proprietary technologies, Seqitope™ and Opti-mAb™, that enable high-resolution and high throughput epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells.

AAX Biotech AB's team is comprised of highly qualified experts, all with PhDs in relevant fields, and their mission is to innovate and solve unmet needs in antibody-based medicine development. They aim to be a leading partner for the global biopharmaceutical industry focusing on a broad range of diseases including cancer, autoimmune disorders, and neurological conditions. The company is committed to providing unparalleled expertise and innovative technologies that contribute to the advancement of novel antibody therapeutics.

Seqitope™ is a high-resolution, high throughput method for antibody epitope mapping that accelerates the development of efficacious therapeutics. On the other hand, Opti-mAb™ is a new scFv format with dramatically improved expression levels and reduced aggregation tendencies, which will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies.

AAX Biotech AB, headquartered in Sweden, presents an exciting opportunity for investment in the field of Biotechnology. With their focus on leveraging science and innovation to accelerate the development of next-generation antibody therapeutics, the company has the potential to make a significant impact on the biopharmaceutical industry.